Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the brain Aminopeptidase A.

The objective of Quantum Genomics is to become a leading actor in the treatment of cardiovascular diseases through the development of a new therapeutic class: BAPAIs for Brain Aminopeptidase A Inhibitors.

Quantum Genomics wishes to develop and provide new effective and well tolerated therapeutic treatments for high blood pressure and for preventing related cardio-vascular risks such as heart failure.

The mid-term strategic objective of the company is to sign partnership agreements with major pharmaceutical companies which will take over and bring the products from the BAPAI technology to the market.